[go: up one dir, main page]

AU2444899A - Pharmaceutical formulation comprising an antibody and a citrate buffer - Google Patents

Pharmaceutical formulation comprising an antibody and a citrate buffer

Info

Publication number
AU2444899A
AU2444899A AU24448/99A AU2444899A AU2444899A AU 2444899 A AU2444899 A AU 2444899A AU 24448/99 A AU24448/99 A AU 24448/99A AU 2444899 A AU2444899 A AU 2444899A AU 2444899 A AU2444899 A AU 2444899A
Authority
AU
Australia
Prior art keywords
antibody
pharmaceutical formulation
citrate buffer
citrate
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU24448/99A
Inventor
Ola Flink
Sven Petren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9800170A external-priority patent/SE9800170D0/en
Priority claimed from SE9800766A external-priority patent/SE9800766D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2444899A publication Critical patent/AU2444899A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU24448/99A 1998-01-22 1999-01-15 Pharmaceutical formulation comprising an antibody and a citrate buffer Abandoned AU2444899A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE9800170A SE9800170D0 (en) 1998-01-22 1998-01-22 formulation
SE9800170 1998-01-22
SE9800766 1998-03-09
SE9800766A SE9800766D0 (en) 1998-03-09 1998-03-09 formulation
PCT/SE1999/000049 WO1999037329A1 (en) 1998-01-22 1999-01-15 Pharmaceutical formulation comprising an antibody and a citrate buffer

Publications (1)

Publication Number Publication Date
AU2444899A true AU2444899A (en) 1999-08-09

Family

ID=26663196

Family Applications (1)

Application Number Title Priority Date Filing Date
AU24448/99A Abandoned AU2444899A (en) 1998-01-22 1999-01-15 Pharmaceutical formulation comprising an antibody and a citrate buffer

Country Status (3)

Country Link
AR (1) AR017973A1 (en)
AU (1) AU2444899A (en)
WO (1) WO1999037329A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2601882T5 (en) 1999-04-09 2021-06-07 Kyowa Kirin Co Ltd Procedure to monitor the activity of an immunofunctional molecule
US20030124119A1 (en) * 1999-12-28 2003-07-03 Tadao Yamazaki Stable antibody compositions and injection preparations
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
WO2005005636A1 (en) 2003-07-15 2005-01-20 Chugai Seiyaku Kabushiki Kaisha IgM PRODUCTION BY TRANSFORMED CELL AND METHOD OF QUANTIFYING THE SAME
HUE026793T2 (en) * 2003-10-01 2016-07-28 Kyowa Hakko Kirin Co Ltd Method of stabilizing antibody and stabilized solution-type antibody preparation
WO2005035573A1 (en) * 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing proteion solutions
EP1688432B1 (en) 2003-10-09 2011-08-03 Chugai Seiyaku Kabushiki Kaisha Igm high concentration stabilized solution
US20070184050A1 (en) * 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
AU2005226736B2 (en) * 2004-03-24 2009-11-26 Abbvie Biotherapeutics Inc. Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
NZ571757A (en) * 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
WO2013103783A1 (en) * 2012-01-04 2013-07-11 Sanofi Us Murine il-13 antibodies
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
PE20150964A1 (en) 2012-09-07 2015-07-25 Coherus Biosciences Inc STABLE AQUEOUS FORMULATIONS OF ADALIMUMAB
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
US11071782B2 (en) 2016-04-20 2021-07-27 Coherus Biosciences, Inc. Method of filling a container with no headspace

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011298A1 (en) * 1988-05-27 1989-11-30 Centocor, Inc. Formulation for antibody reagents
JPH04504253A (en) * 1989-03-27 1992-07-30 セントカー・インコーポレーテツド Formulations for the stabilization of IgM antibodies
JPH0565233A (en) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc Monoclonal antibody-containing lyophilized preparation
CA2507749C (en) * 1991-12-13 2010-08-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9325182D0 (en) * 1993-12-08 1994-02-09 T Cell Sciences Inc Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions

Also Published As

Publication number Publication date
AR017973A1 (en) 2001-10-24
WO1999037329A1 (en) 1999-07-29

Similar Documents

Publication Publication Date Title
AU2444899A (en) Pharmaceutical formulation comprising an antibody and a citrate buffer
AU7912100A (en) Pharmaceutical composition comprising an antigen
AU5020400A (en) Heteroaryloxypyrimidine insecticides and acaricides
AU5440901A (en) Cosmetic and/or pharmaceutical preparations
AU2543399A (en) Anticonvulsant drugs and pharmaceutical compositions thereof
AU3159499A (en) Antigen preparation and use
AU3117400A (en) Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
AU3472799A (en) Dermatological formulations and methods
AU6124999A (en) Hydrazinooxoacetamide derivatives and insecticide
AU6213699A (en) Nutritional and pharmaceutical compositions
AU2438400A (en) Cosmetic and/or pharmaceutical preparations
AU4777100A (en) Nutraceuticals and ingredients for functional foods
AU6422298A (en) Pharmaceutical composition containing a phosphorylamide and an ayntibiotic
AU4293800A (en) Cosmetic and/or pharmaceutical preparations
AUPP672198A0 (en) Pyrazolopyridine compound and pharmaceutical use thereof
AU3357700A (en) Phenoxypyrimidine insecticides and acaricides
AU6179600A (en) Peptides and pharmaceutical compositions comprising same
AU1053501A (en) Polyazanaphthalene compound and medicinal use thereof
AU2136401A (en) P450rai-2 and related proteins
AU1800100A (en) Medicinal preparations
AU7681498A (en) Pharmaceutical composition and use thereof
AU7711096A (en) Cisplatinum comprising pharmaceutical
AUPP363498A0 (en) Antigens and their detection
AU2880699A (en) Pharmaceutical compositions and methods for use
AU2001252921A1 (en) A glycopeptide and preparation thereof

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase